INFORMATION CONCERNING A NEW STUDY FOR ALPHA1-ANTITRYPSIN DEFICIENCY AND EMPHYSEMA IN CENTRAL CANADA
Currently we are looking for individuals who may be interested in participating in a clinical research trial of an inhaled human Alpha-1 Antitrypsin preparation. This study is a randomized, placebo-controlled trial. This means that there is a 50% chance of receiving the active medication and a 50 % chance of receiving no active medication, a placebo. Neither you nor the study doctor will know whether you are receiving active medication or placebo.
The study medication is a liquid preparation of human alpha-1 antitrypsin (AAT), also called alpha-1 protein inhibitor. Subjects will receive two daily inhalations (in morning and afternoon) of the study medications.
To be eligible you
- must be at least 18 years or older
- Record of an AAT deficiency
- Non smoker or have quit for at least 12 months
- Demonstrate airflow obstruction.
- History of at least 2 exacerbations that have required medications and/or hospitalization in the past 18 months.
- Not receiving IV augmentation therapy i.e. Prolastin or equivalent the past 6 months
If you are interested or would like more information on the study please contact Jane, Jeff or Heather, study coordinators at Inspiration Research Limited. The study is under the direction of Dr. Kenneth Chapman.
Call 416 944 9602, to speak to Jane Duke or Jeff He or e-mail firstname.lastname@example.org or email@example.com